Australia markets open in 5 hours 5 minutes
  • ALL ORDS

    7,051.00
    +36.00 (+0.51%)
     
  • AUD/USD

    0.7740
    +0.0045 (+0.58%)
     
  • ASX 200

    6,770.40
    +27.80 (+0.41%)
     
  • OIL

    53.38
    +0.40 (+0.76%)
     
  • GOLD

    1,862.90
    +22.70 (+1.23%)
     
  • BTC-AUD

    45,226.55
    +629.36 (+1.41%)
     
  • CMC Crypto 200

    691.25
    -9.36 (-1.34%)
     

China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level

·2-min read

HONG KONG, Dec 21, 2020 - (ACN Newswire) - Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. China Medical System's ESG Rating has been upgraded from "BBB" to "AA", surpassing 88% of companies in the global pharmaceutical industry, symbolizing that the Company has attained a level among its global peers in ESG management.

MSCI recognized China Medical System's outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development, and Access to Health Care, noting that the Company "Leads peers in business ethics and talent management practices". MSCI also gave a positive assessment of the Company's Corporate Behavior, "China Medical System has evidence of detailed policies on business ethics and corruption".

There are seven levels of the MSCI-ESG Rating, from the highest to the lowest are AAA, AA, A, BBB, BB, B, and CCC. Among them, companies with AA or AAA ratings are considered to be industry leaders in managing the most significant ESG risks and opportunities. This year, China Medical System's MSCI-ESG Rating has been upgraded by three levels, from BB to AA.

According to the Company, "Receiving the AA ESG Rating from MSCI reflected China Medical System's long-term focus and resource investment on ESG management and information disclosure, and affirmed the Company's compliance focus and solid business practices. In recent years, with leadership from the Board of Directors, the Company's ESG-related policies have increasingly improved, ESG practices are more standardized, and ESG management is constantly refined.

"In the future, through self-challenge and transcendence, China Medical System will continuously pursue higher corporate governance goals. The Company will continuously regard innovation as its driving force, to fulfill the unmet medical needs, and contribute to the integrated development of society, the environment, and civilization."


Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com